Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0UGBDK
ADC Name	Anti-B7H3 APDC 3f
Synonyms	Anti-B7H3-APDC-3f Click to Show/Hide
Drug Status	Investigative
Indication	In total 2 Indication(s) Glioblastoma [ICD11:2A00] Investigative Head and neck squamous carcinoma [ICD11:2C31] Investigative
Drug-to-Antibody Ratio	3.9
	3D MOL	2D MOL
Antibody Name	TPP-8567		Antibody Info
Antigen Name	CD276 antigen (CD276)		Antigen Info
Payload Name	Kinesin spindle protein (KSP) inhibitor 3f		Payload Info
Therapeutic Target	Kinesin-like protein KIF11 (KIF11)		Target Info
Linker Name	Open-chain glycine maleimide		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 90.04	%	U-251MG cells	Astrocytoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	SCC-4 cells	Tongue squamous cell carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.04% (Day 30)	Positive B7H3 expression (B7H3 +++/++)
Method Description	Both APDCs (10 mg/kg) have been administered to B7H3-positive U251-glioma-tumor-bearing mice; 24hours after treatment, tumors and organs were collected.
In Vivo Model	U251 CDX model
In Vitro Model	Astrocytoma	U-251MG cells		CVCL_0021
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 50)	Positive B7H3 expression (B7H3 +++/++)
Method Description	In the B7H3-positive, slowly growing head and neck squamous cell carcinoma model SCC4, APDC 3 g at a dose of 10 mg/kg given 3 times in a weekly schedule which favorably compared to cisplatin and radiation therapy.
In Vivo Model	SCC4 CDX model
In Vitro Model	Tongue squamous cell carcinoma	SCC-4 cells		CVCL_1684

References

Ref 1	Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation. Chemistry. 2019 Jun 21;25(35):8208-8213. doi: 10.1002/chem.201900441. Epub 2019 Apr 15.